The fact that wild-type IDH1 is causally related to clinical cases of low-grade gliomas lends support to our own findings of its upregulation in the Ezh2 gain-of-function ‘tumors’, presenting similar features. The gene discussed is EZH2; the disease is central nervous system cancer.